Clinical Trial Update: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial update notes the addition of Loncastuximab tesirine to acalabrutinib for chronic lymphocytic leukemia; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Loncastuximab tesirine (loncastuximab tesirine)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING